1579965-12-0Relevant academic research and scientific papers
Discovery of a first-in-class receptor interacting protein 2 (RIP2) kinase specific clinical candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate, for the treatment of inflammatory diseases
Haile, Pamela A.,Casillas, Linda N.,Votta, Bartholomew J.,Wang, Gren Z.,Charnley, Adam K.,Dong, Xiaoyang,Bury, Michael J.,Romano, Joseph J.,Mehlmann, John F.,King, Bryan W.,Erhard, Karl F.,Hanning, Charles R.,Lipshutz, David B.,Desai, Biva M.,Capriotti, Carol A.,Schaeffer, Michelle C.,Berger, Scott B.,Mahajan, Mukesh K.,Reilly, Michael A.,Nagilla, Rakesh,Rivera, Elizabeth J.,Sun, Helen H.,Kenna, John K.,Beal, Allison M.,Ouellette, Michael T.,Kelly, Mike,Stemp, Gillian,Convery, Maíre A.,Vossenk?mper, Anna,Macdonald, Thomas T.,Gough, Peter J.,Bertin, John,Marquis, Robert W.
, p. 6482 - 6494 (2019/08/20)
RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on
PRODRUGS OF AMINO QUINAZOLINE KINASE INHIBITOR
-
, (2014/04/03)
Disclosed are compounds having Formula (I); wherein X is as defined herein, and methods of making and using the same.
